Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
The Oncologist
|
July 7, 2016
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib
Daniel Keizman, David Sarid, Jae L Lee, et al.
Clinical Genitourinary Cancer
|
November 27, 2019
Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer
Orazio Caffo, Michel Wissing, Diletta Bianchini, et al.
The Oncologist
|
December 7, 2013
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib
Daniel Keizman, Maya Gottfried, Maya Ish-Shalom, et al.
Clinical Genitourinary Cancer
|
November 23, 2024
Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial
Ronac Mamtani, Nobuaki Matsubara, Alvaro Montesa Pino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
David C Smith, Matthew R Smith, Christopher Sweeney, et al.
Oncotarget
|
April 19, 2013
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care
Richard E Kast, John A Boockvar, Ansgar Brüning, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2019
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database
Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 30, 2020
Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]
Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2020
Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]
Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Urology Oncology
|
June 4, 2019
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database
Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
The Oncologist
|
July 7, 2016
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib
Daniel Keizman, David Sarid, Jae L Lee, et al.
Clinical Genitourinary Cancer
|
November 27, 2019
Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer
Orazio Caffo, Michel Wissing, Diletta Bianchini, et al.
The Oncologist
|
December 7, 2013
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib
Daniel Keizman, Maya Gottfried, Maya Ish-Shalom, et al.
Clinical Genitourinary Cancer
|
November 23, 2024
Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial
Ronac Mamtani, Nobuaki Matsubara, Alvaro Montesa Pino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
David C Smith, Matthew R Smith, Christopher Sweeney, et al.
Oncotarget
|
April 19, 2013
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care
Richard E Kast, John A Boockvar, Ansgar Brüning, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2019
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database
Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 30, 2020
Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]
Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2020
Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]
Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Urology Oncology
|
June 4, 2019
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database
Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
Page
of 5